Intestinal Ultrasound for Monitoring IBD: JCC | July 2026

Introduction:

Endoscopy remains the gold standard for assessing inflammatory bowel disease (IBD) activity but is invasive, costly, and resource-intensive. This real-world study evaluated whether integrating intestinal ultrasound (IUS) into routine IBD care could reduce the need for endoscopic assessment.

Why was this study needed?

• Endoscopy is invasive and not always acceptable to patients.
• Increasing IBD prevalence has placed significant pressure on endoscopy services.
• Intestinal ultrasound is a rapid, non-invasive bedside tool for disease monitoring.
• Long-term real-world data on the impact of IUS implementation have been limited.
• Alternative monitoring strategies are needed to improve efficiency and reduce healthcare costs.

Results:

• Introducing intestinal ultrasound reduced endoscopy use for IBD activity assessment by more than 50%, despite a marked increase in outpatient clinic visits.
• More than 3,300 IUS examinations were performed, successfully monitoring both active disease and treatment-induced remission in patients with Crohn's disease and ulcerative colitis.
• The findings suggest that IUS can safely replace many monitoring endoscopies, potentially reducing waiting lists, improving patient convenience, and lowering healthcare costs.

Clinical Impact:

This study supports intestinal ultrasound as a first-line monitoring tool for IBD in routine clinical practice. Wider adoption of IUS could transform IBD care by providing rapid, repeatable, point-of-care assessment while reserving endoscopy for diagnosis, dysplasia surveillance, and selected therapeutic decisions.

Bottom Line:

Intestinal ultrasound has the potential to become the primary disease-monitoring tool in IBD. Its integration into routine practice substantially reduces the need for endoscopy while maintaining effective assessment of disease activity and remission.